Company Focus
Ipsen
Latest Ipsen News
Pharmaceutical
Japanese drugmaker Eisai has announced that the administration of the anticancer agent EZH2 inhibitor Tazverik tablets 200mg (tazemetostat hydrobromide), which is manufactured and marketed in Japan by Eisai should be discontinued.]- 21 March 2026
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders.
Latest News & Features of interest to Ipsen
Biotechnology
German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment. 11 April 2026
Pharmaceutical
The UK’S Medicines and Healthcare products Regulatory Agency (MHRA) has approved Swedish Orphan Biovitrum Tryngolza (olezarsen) to help treat adults with familial chylomicronemia syndrome (FCS). 11 April 2026
Pharmaceutical
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 to US-based Click Therapeutics, reshaping a partnership first struck in 2020. 10 April 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Pharmaceutical
USA-based neurodegenerative disorders specialist Annovis Bio today revealed that it has secured financing to support the development of its investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. 10 April 2026
Pharmaceutical
Tempus AI , a technology company leading the adoption of AI to advance precision medicine, has announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline. 10 April 2026
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience saw its shares jump 28.7% to 0.20 kronor this morning, after it provided a brief update regarding its mitazalimab. 10 April 2026
Biotechnology
US clinical-stage biotech C4 Therapeutics (C4T) announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate (DAC) modality. 10 April 2026
Pharmaceutical
US pharma major AbbVie has filed a lawsuit seeking to narrow the definition of a “340B patient,” opening a new legal front in a long-running dispute over the US drug discount program. 9 April 2026
Pharmaceutical
US biotech Sidewinder Therapeutics has secured $137 million in an oversubscribed series B financing to advance its bispecific antibody-drug conjugate (ADC) pipeline for cancer. 9 April 2026
Latest In Brief for Ipsen
Pharmaceutical
Shares of Indian drug major Sun Pharmaceutical Industries declined sharply in trade on the Bombay Stock Exchange, as investor sentiment turned cautious following reports of a potential large acquisition. 10 April 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze